Showing posts with label arthritis. Show all posts
Showing posts with label arthritis. Show all posts

Monday, April 18, 2011

FDA approves Actemra to treat rare form of juvenile arthritis

The U.S. Food and Drug Administration today approved Actemra (tocilizumab), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in children ages 2 years and older.

SJIA, or Still’s disease, is a rare, potentially life-threatening disorder in children that causes severe inflammation throughout the body. SJIA is distinguished from other forms of juvenile idiopathic arthritis (JIA) by the prominence of systemic and inflammatory features, including spiking fevers; rash; swelling and inflammation of lymph nodes, liver, and spleen; and high white blood cell and platelet counts. The prevalence of JIA is an estimated 1 to 2 per 1,000 children, and SJIA affects about 10 percent of all JIA patients.

Actemra is an interleukin-6 receptor blocker approved by the FDA on Jan. 8, 2010, for treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to other approved therapies.

“This new indication of Actemra provides the first approved therapy for children with this rare disease,” said Badrul Chowdhury, M.D., Ph.D., director of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research.

An international, multicenter controlled trial demonstrated the safety and effectiveness of Actemra, in which 112 patients received either Actemra infusions or placebo infusions every two weeks. Study participants included patients with SJIA aged 2 to 17 years old who had inadequate response to or who were unable to take nonsteroidal anti-inflammatory drugs and corticosteroids.

Eighty-five percent of those receiving Actemra responded to treatment, compared with 24 percent of patients receiving placebo. Response was defined as at least 30 percent improvement in the American College of Rheumatology’s JIA efficacy variables, along with absence of fever in the preceding seven days. In the long-term, follow-up period of the trial there were three cases of macrophage activation syndrome (MAS) among SJIA patients receiving Actemra. MAS is a potentially fatal complication of childhood systemic inflammatory disorders, thought to be caused by excessive activation and proliferation of certain immune cells.

Actemra carries a Boxed Warning for serious infections. Patients treated with Actemra who develop a serious infection should stop Actemra treatment until the infection is controlled. A Boxed Warning is a brief, concise summary of the information that is critical for a prescriber to be aware of, including any restriction on distribution or use, which is included in a black box at the beginning of the drug label.

Changes in certain laboratory test results such as liver tests, blood counts, and cholesterol are not uncommon with Actemra and should be monitored with regular blood tests. The most common side effects in trial participants with SJIA included upper respiratory tract infection, headache, sore throat, and diarrhea.

Actemra is marketed by San Francisco-based Genentech Inc., a subsidiary of the Roche Group.

-----

Community News You Can Use
Click to read MORE news:
www.GeorgiaFrontPage.com
Twitter: @gafrontpage & @TheGATable @HookedonHistory
www.ArtsAcrossGeorgia.com
Twitter: @artsacrossga, @softnblue, @RimbomboAAG @FayetteFP

Thursday, September 23, 2010

House Committee Approves Arthritis Bill

/PRNewswir/ -- The Arthritis Foundation announces a major step in passing bi-partisan arthritis legislation in more than 30 years. The Arthritis Prevention, Control and Cure Act (H.R. 1210/S. 984) was approved today by the House Energy and Commerce Committee and will now go to the House of Representatives to vote on passage.

Bill sponsor U.S. Rep Anna Eshoo (D-Calif.) urged the committee leadership to pass the bill in order to address arthritis, a disease that impacts one in five (46 million) Americans and 300,000 children and is the nation's most common cause of disability.

"I'm very proud that my bipartisan legislation has been passed by the Energy and Commerce Committee. The bill will provide states and non-profits the resources they need to tackle this debilitating disorder," Rep. Eshoo said. "It invests in the critical needs of children and adults suffering from arthritis, and in research that will alleviate the costs to future generations of Americans who are diagnosed. I'll continue to fight for this legislation until it's signed into law."

The Arthritis Prevention, Control and Cure Act, when enacted, will better focus federally funded arthritis research, expand and strengthen public health initiatives proven to combat the burden of arthritis, and improve access to pediatric rheumatologists to address the country's severe shortage of these critical health professionals.

"The Arthritis Foundation is comprised of people all across this nation who have worked tirelessly over the past seven years to let Congress know that more needs to be done for people with arthritis," said Dr. John Klippel, president and CEO of the Arthritis Foundation. "Our grassroots advocates deserve to be recognized for reaching and successfully communicating this message to the majority of Congress." To date, 179 Representatives have joined as co-sponsors of the bill.

The Arthritis Foundation urges people to show support for this bill by calling their member of congress and becoming an advocate today.

-----
Community News You Can Use
Click to read MORE news:
www.GeorgiaFrontPage.com
Twitter: @gafrontpage & @TheGATable @HookedonHistory
www.ArtsAcrossGeorgia.com
Twitter: @artsacrossga, @softnblue, @RimbomboAAG
www.FayetteFrontPage.com
Twitter: @FayetteFP

Thursday, April 15, 2010

Arthritis Impacts African-Americans and Hispanics More than Whites

/PRNewswire/ -- Arthritis causes more pain and limitations for African-Americans and Hispanics than for whites, according to a study released today by the Centers for Disease Control and Prevention.

African-Americans were 17 percent less likely to report having arthritis than whites, and Hispanics were 46 percent less likely to report the condition than whites, the study said. However, African-Americans and Hispanics with arthritis were almost twice as likely to report severe joint pain and work limitations attributed to their arthritis when compared to whites, it said.

The study, "Difference in the Prevalence and Impact of Arthritis among Racial / Ethnic Groups," was published in the journal Preventing Chronic Disease.

Arthritis is the leading cause of disability in the United States, affecting 1 in 5 adults. It interferes with work and other daily activities and can complicate the management of other chronic diseases. Arthritis encompasses more than 100 diseases and conditions that affect joints and other connective tissue.

The reason for the racial and ethnic differences, while unknown, may result from a lack of access to health care, language barriers and cultural differences, the report says.

"We must address these stark differences in arthritis impact by using what we know,'' said Jennifer Hootman, an epidemiologist for the CDC National Center for Chronic Disease Prevention and Health Promotion and co-author of the report. "We can educate those with arthritis about increasing physical activity and self-management and reducing obesity, especially those in groups bearing a disproportionate burden from arthritis."

The data, collected from the CDC National Health Interview Survey, are the first to estimate the national prevalence of arthritis and assess its impact among smaller racial and ethnic groups that are usually grouped together when reporting health statistics.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter:  @GAFrontPage

Sunday, August 2, 2009

FDA Approves Colchicine for Acute Gout, Mediterranean Fever

The U.S. Food and Drug Administration has approved Colcrys to treat acute flairs in patients with gout, a recurrent and painful form of arthritis, and patients with familial Mediterranean fever (FMF), an inherited inflammatory disorder. The medication’s active ingredient is colchicine, a complex compound derived from the dried seeds of a plant known as the autumn crocus or meadow saffron (Colchicum autumnale).

Colchicine has been used by healthcare practitioners for many years to treat gout but had not been approved by the FDA. The FDA has an initiative underway to bring unapproved, marketed products like colchicine under its regulatory framework. This initiative promotes the goal of assuring that all marketed drugs meet modern standards for safety, effectiveness, quality and labeling.

Physicians historically have given colchicine hourly for acute gout flares until the flare subsided or they had to stop treatment because the patient began experiencing gastrointestinal problems. A dosing study required as part of FDA approval demonstrated that one dose initially and a single additional dose after one hour was just as effective as continued hourly dosing for acute gout flares, but much less toxic. As a result, the drug is being approved for acute gout flares with the lower recommended dosing regimen.

The FDA is alerting healthcare professionals to this new dosing regimen and also warning about the potential for severe drug interactions when patients take colchicine.

The medicinal value of using colchicum was first identified in the first century A.D. and its use for treating acute gout dates back to 1810. Physicians have prescribed the medication since then. Although single-ingredient colchicine has not been approved by the FDA until now, a combination product containing colchicine and an agent that increased the excretion of uric acid in the urine was approved by the FDA in 1939.

FMF is the most common of the hereditary periodic fever syndromes and is characterized by recurrent episodes of fever, arthritis and painful inflammation of the lining layers of the lungs and abdomen. Though rare in the United States, it is more common in Mediterranean countries. Physicians have prescribed colchicine for FMF for many years based on studies showing that it reduced the frequency of attacks but use of colchicine for FMF had never been approved. With this approval, Colcrys becomes the first drug approved to treat FMF.

Colcrys is manufactured by Mutual Pharmaceutical Company, Inc., Philadelphia.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Thursday, May 28, 2009

FDA Approves New Total Ankle Replacement System

The U.S. Food and Drug Administration today approved a total ankle replacement system for arthritic or deformed ankles that may preserve some range of motion in the joint.

The new prosthesis is a mobile-bearing device, which relies on bearings that move across a surface of polyethylene, a flexible plastic. The device is the first of its type.

Once arthritis or injury destroys the cartilage that cushions the ankle bone, the joints can become painful enough to warrant total ankle replacement.

The Scandinavian Total Ankle Replacement (STAR) System is an alternative to fusion surgery and may allow for greater rotation and movement in the joint. Fusion surgery involves cementing the shin bone (tibia) – the thicker of the two bones in the lower leg – to the talus bone in the ankle. The procedure stabilizes the ankle, but significantly decreases the ability to move the foot up and down.

“This device offers another treatment alternative to fusion surgery, and more closely imitates the function of a natural ankle,” said Daniel G. Schultz, M.D., director of the FDA’s Center for Devices and Radiological Health. “For the first time in the United States, a patient may retain some ankle mobility with this non-constrained, mobile-bearing device.”

The FDA has already cleared several fixed-bearing ankle devices, which are also options to fusion surgery. In fixed-bearing ankle system, the articulating surface is molded, locked or attached to one of its metallic components.

For two years, researchers followed a subgroup of a 224-patient clinical study and found that the STAR system demonstrated similar rates of adverse events, surgical interventions and major complications as fusion surgery.

As a condition of FDA approval, the company will evaluate the safety and effectiveness of the device during the next eight years.

The STAR Ankle is owned by Small Bone Innovations Inc. of Morrisville, Pa.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
www.artsacrossgeorgia.com
Arts Across Georgia

Thursday, April 30, 2009

Number of U.S. Adults Reporting Disabilities is Increasing

The number of U.S. adults reporting a disability increased by 3.4 million between 1999 and 2005, according to a recent report released by the Centers for Disease Control and Prevention.

The study in today's Morbidity and Mortality Weekly Report also finds an estimated 1 in 5 U.S. adults (47.5 million, or 21.8 percent) report a disability. The three most common causes of disability among adults in the United States are arthritis or rheumatism, back or spine problems, and heart disease.

"It is likely we will see more dramatic increases in the number of adults with a disability as the baby boomer population begins to enter higher risk, older age groups over the next 20 years," said Chad Helmick, M.D., CDC medical epidemiologist and coauthor of the study. "CDC is working with state health departments and communities to expand the availability of self-management education programs and interventions, such as appropriate physical activity programs, that can reduce the impact of disability."

The study of data collected from the U.S. Census Bureau's Survey of Income and Program Participation found that women (24.4 percent) have a higher prevalence of disability compared with men (19.9 percent) at all ages. The study also found that disability prevalence doubled for each successive age group - 11.0 percent for ages 18-44, 23.9 percent for ages 45-64, and 51.8 percent for ages 65 or older.

Arthritis encompasses more than 100 diseases and conditions that affect joints and other connective tissue. For more information on arthritis visit www.cdc.gov/arthritis. For information on disabilities visit www.cdc.gov/ncbddd/disabilities.htm. For information on heart disease visit http://www.cdc.gov/heartdisease.

Number of U.S. Adults Reporting Disabilities is Increasing

The number of U.S. adults reporting a disability increased by 3.4 million between 1999 and 2005, according to a recent report released by the Centers for Disease Control and Prevention.

The study in today's Morbidity and Mortality Weekly Report also finds an estimated 1 in 5 U.S. adults (47.5 million, or 21.8 percent) report a disability. The three most common causes of disability among adults in the United States are arthritis or rheumatism, back or spine problems, and heart disease.

"It is likely we will see more dramatic increases in the number of adults with a disability as the baby boomer population begins to enter higher risk, older age groups over the next 20 years," said Chad Helmick, M.D., CDC medical epidemiologist and coauthor of the study. "CDC is working with state health departments and communities to expand the availability of self-management education programs and interventions, such as appropriate physical activity programs, that can reduce the impact of disability."

The study of data collected from the U.S. Census Bureau's Survey of Income and Program Participation found that women (24.4 percent) have a higher prevalence of disability compared with men (19.9 percent) at all ages. The study also found that disability prevalence doubled for each successive age group -- 11.0 percent for ages 18-44, 23.9 percent for ages 45-64, and 51.8 percent for ages 65 or older.

Arthritis encompasses more than 100 diseases and conditions that affect joints and other connective tissue. For more information on arthritis visit www.cdc.gov/arthritis. For information on disabilities visit www.cdc.gov/ncbddd/disabilities.htm. For information on heart disease visit http://www.cdc.gov/heartdisease.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter @GAFrontPage

Wednesday, June 4, 2008

Arthritis Drugs and Cancer?

HHH Note: Sometimes, articles just catch our eyes. This one really made us sit back and think. What kind of future are we giving some of our youth?

All drug manufacturers are required to provide adverse reaction data to the FDA. Sometimes, the data can show some surprising and unexpected results after patient numbers increase dramatically. Does this mean some drugs have to be pulled from the market? What it really means is that we as consumers must investigate the drugs and question the physicians to be sure we are willing to take the risks for ourselves and our children. If you have an adverse reaction to any drug, please make sure your physician knows. You can also alert the FDA. They will keep the information on file.


FDA Probes Arthritis Drug Link To Cancer

June 4, 2008
The U.S. Food and Drug Administration has announced an investigation into a class of drugs used to treat arthritis, over concerns they might be linked to the development of cancer....

Read the story.

Wednesday, January 23, 2008

Arthritis Foundation Announces Top 10 Arthritis Advances of 2007

PRNewswire-USNewswire/ -- A team of engineers have recently created a new framework upon which cartilage tissue can be grown. The novel scaffold is porous, so the fabric can be seeded with cells and transplanted into a joint damaged by arthritis. The woven "fabric" will be absorbed by the body, leaving only healthy, strong cartilage for those who suffer from osteoarthritis or other cartilage injuries. This is just one of the top 10 most significant arthritis advances of 2007, according to the Arthritis Foundation.

The Arthritis Foundation's annual Top 10 Arthritis Advances also includes a survey released by the Centers for Disease Control and Prevention (CDC) quantifying the high cost of arthritis, in which arthritis-attributable work limitation affects one in three working-age adults (aged 18-64 years) with doctor-diagnosed arthritis. Another important advance this past year was the first ever quantification of the number of children with juvenile arthritis and documentation of the severe shortage of pediatric rheumatologists to provide diagnosis and care for children with juvenile arthritis in the United States. Moreover, several approaches were identified to increase access to subspecialty care by pediatric rheumatologists, which include enhancing the availability and financing of fellowship training to increase the number of trainees in the field and also improving the financial viability of pediatric rheumatology practices in academic settings.

"As the prevalence of arthritis continues to soar in the United States, advances made in 2007 provide the groundwork for improving the lives of the 46 millions people who live with arthritis now and the 40% more projected to be affected by 2030," said John H. Klippel, M.D., president and CEO of the Arthritis Foundation. "With arthritis being the most common cause of disability, advances in research and the development of more effective and safer treatments will continue to contribute in helping to improve the quality of life for people with arthritis."

The Arthritis Foundation's Top 10 Arthritis Events of 2007 include:
-- Passage of FDA Legislation on Drug Regulation and Safety
-- Quantification of Work Limitation and Earnings Losses

-- Projections of Increases in Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation

-- Identification of RA Susceptibility Genes STAT4 and TRAF1-C5
-- Uncovering the Importance of Cadherin-11
-- Development of a Woven Mesh for Cartilage Engineering
-- Approval of Lyrica for Treatment of Fibromyalgia
-- Availability of NIH's Osteoarthritis Data and Images
-- Quantification of Children with Arthritis and Number of Doctors Needed
-- Evidence of Benefit and Safety of Biologic Therapy in Children

Summaries of each of the top arthritis advances, as well as what they mean for arthritis patients are available at http://www.arthritis.org/top-10-2007.php

To develop its fifth annual list of the Top 10 Arthritis Advances, the Arthritis Foundation sought input from clinicians with expertise in various forms of arthritis, scientists from a wide variety of research disciplines, and organizations with an interest in arthritis and related diseases.